Assessment of Spontaneous Baroreflex Sensitivity in Carriers of Implantable Cardioverter Defibrillators: Association With Disorders of the Ventricular Heart Rate. Case-control Study (BARODEF)

Poitiers University Hospital

Status: Completed

Conditions: Myocardial Infarction

Treatments: Other: Baroreflex assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT02930382

BARODEF

Details and patient eligibility

About

We must implement 8 implantable cardioverter defibrillators (ICDs) to save a life in 3 years after myocardial infarction (MI) in primary prevention.

Left ventricular ejection fraction (LVEF) is proposed as the one tool predicting sudden cardiac death after MI.

Several studies have shown that impairment of spontaneous baroreflex sensitivity (BRS) after MI was predictor of sudden death.

Enrollment: 48 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients implanted with an implantable cardioverter defibrillator for primary prevention of of cardiac sudden death, ischaemic cardiomyopathy
• Implantable cardioverter defibrillators implantation for at least 3 years
• Age ≥ 18 years

Exclusion criteria

• ventricular or atrial pacing ≥1%,
• atrial fibrillation history
• age under 18 years

Trial design

48 participants in 1 patient group

BAROREFLEX

Experimental group

Treatment:

Other: Baroreflex assessment